These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 38422895)

  • 1. Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis.
    Bartoletti M; Montico M; Lorusso D; Mazzeo R; Oaknin A; Musacchio L; Scambia G; Puglisi F; Pignata S
    Cancer Treat Rev; 2024 Apr; 125():102701. PubMed ID: 38422895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of immune-checkpoint inhibitors combined with cytotoxic chemotherapy in advanced or recurrent endometrial cancer: A systematic review and meta-analysis.
    Kim JH; Han KH; Park EY; Kim ET; Kim EJ; Tan DSP; Lee JY; Park SY; Fotopoulou C; Lim MC
    Gynecol Oncol; 2024 Aug; 187():85-91. PubMed ID: 38735144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials.
    de Moraes FCA; Pasqualotto E; Lopes LM; Cavalcanti Souza ME; de Oliveira Rodrigues ALS; de Almeida AM; Stecca C; Fernandes MR; Dos Santos NPC
    BMC Cancer; 2023 Nov; 23(1):1166. PubMed ID: 38031003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
    Westin SN; Moore K; Chon HS; Lee JY; Thomes Pepin J; Sundborg M; Shai A; de la Garza J; Nishio S; Gold MA; Wang K; McIntyre K; Tillmanns TD; Blank SV; Liu JH; McCollum M; Contreras Mejia F; Nishikawa T; Pennington K; Novak Z; De Melo AC; Sehouli J; Klasa-Mazurkiewicz D; Papadimitriou C; Gil-Martin M; Brasiuniene B; Donnelly C; Del Rosario PM; Liu X; Van Nieuwenhuysen E;
    J Clin Oncol; 2024 Jan; 42(3):283-299. PubMed ID: 37864337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety evaluation of frontline immunotherapy combinations in advanced esophageal squamous cell carcinoma: a network meta-analysis highlighting the value of PD-L1 expression positivity scores.
    Chen W; Cao K; Zhang L; Zhao X; Chen B; Li W; Shang R; Sun L; Jiang Z; Wang J; Xue W
    Front Immunol; 2024; 15():1414753. PubMed ID: 39050848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
    Li Y; Liang X; Li H; Chen X
    Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1/PD-L1 Inhibitors Monotherapy for the Treatment of Endometrial Cancer: Meta-Analysis and Systematic Review.
    Dai Y; Muaibati M; Xie W; Abasi A; Li K; Tong Q; Zhang T; Meng Y; Zhuang L; Huang X
    Cancer Invest; 2022 Mar; 40(3):293-309. PubMed ID: 34825855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitor combinations for patients with advanced endometrial cancer: a network meta-analysis and cost-utility analysis.
    Zhu Y; Liu K; Zhu H
    Int J Gynecol Cancer; 2024 Oct; 34(10):1570-1579. PubMed ID: 38901970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors plus chemotherapy in first-line endometrial cancer treatment: Still the era of microsatellites?
    Maiorano MFP; Messina C; Maiello E; Cormio G; Maiorano BA
    BJOG; 2024 Jul; 131(8):1157-1159. PubMed ID: 38164107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of single agent PD-1 or PD-L1 inhibition on advanced endometrial cancers: meta-analysis.
    Kok PS; Antill YC; Scott CL; Lee CK
    ESMO Open; 2022 Dec; 7(6):100635. PubMed ID: 36410086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis.
    Conforti F; Pala L; Bagnardi V; Viale G; De Pas T; Pagan E; Pennacchioli E; Cocorocchio E; Ferrucci PF; De Marinis F; Gelber RD; Goldhirsch A
    J Natl Cancer Inst; 2019 Aug; 111(8):772-781. PubMed ID: 31106827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis.
    Brito ABC; Camandaroba MPG; de Lima VCC
    Thorac Cancer; 2021 Apr; 12(7):1058-1066. PubMed ID: 33586297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H; Liu L; Peng Q; Chen J; Zhu YD
    BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis.
    Yang X; Zeng Y; Tan Q; Huang Z; Jia J; Jiang G
    J Immunol Res; 2022; 2022():4518898. PubMed ID: 35637793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups.
    Yap DWT; Leone AG; Wong NZH; Zhao JJ; Tey JCS; Sundar R; Pietrantonio F
    JAMA Oncol; 2023 Feb; 9(2):215-224. PubMed ID: 36480211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized clinical trials.
    Huo X; Shen G; Liu Z; Liang Y; Li J; Zhao F; Ren D; Zhao J
    Crit Rev Oncol Hematol; 2021 Dec; 168():103530. PubMed ID: 34801695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of immune-checkpoint inhibitors in PD-L1 selected or unselected patients vs. control group in patients with advanced or metastatic urothelial carcinoma.
    Guo L; Wang X; Wang S; Hua L; Song N; Hu B; Tong Z
    Oncoimmunology; 2021 Mar; 10(1):1887551. PubMed ID: 33747636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review.
    Maiorano BA; Maiorano MFP; Cormio G; Maglione A; Lorusso D; Maiello E
    Front Oncol; 2022; 12():844801. PubMed ID: 35494078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.